© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Feb 28, 2015, the consensus forecast amongst 27 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 23 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 120.00, with a high estimate of 159.00 and a low estimate of 84.00. The median estimate represents a 16.04% increase from the last price of 103.42. View Full Financials
Historical dividend information is not available for Gilead Sciences Inc. View Full Financials
|Div growth (TTM)||--|
On Feb 03, 2015, Gilead Sciences, Inc. reported 4th quarter 2014 earnings of 2.43 per share. This result exceeded the 2.22 consensus of the 24 analysts covering the company and exceeded last year's 4th quarter results by 1.88.
The next earnings announcement is expected on Apr 20, 2015. View Full Interim Financials
|Average growth rate||+58.49 %|
Gilead Sciences, Inc. reported annual 2014 earnings of 8.09 per share on Feb 03, 2015. View Full Annual Financials
|Average growth rate||+76.71 %|
Gilead Sciences Inc. had 4th quarter 2014 revenues of 7.31bn. This bettered the 6.72bn consensus of the 22 analysts covering the company. This was 21.06% above the prior year's 4th quarter results. View Full Interim Financials
|Average growth rate||+26.12 %|
Gilead Sciences Inc. had revenues for the full year 2014 of 24.89bn. This was 122.20% above the prior year's results. View Full Annual Financials
|Average growth rate||+39.71 %|